List/Grid Tag Archives: refractory
Hu3F8 is now a reality at Memorial-Sloan Kettering
The Story of the Band of Parents and humanized 3F8
by Caryn Franca and Shirley Staples
It was summer of 2007. A group of parents had asked Dr. Nai-Kong Cheung to meet and update them on new treatments for neuroblastoma at Memorial Sloan-Kettering Cancer Center. Most had children with relapsed neuroblastoma; all knew the terrible odds. Dr. Cheung, head of the neuroblastoma program at MSKCC, ...
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
New phase I trial opening soon at University of Alabama, Birmingham
This trial will enroll 6 patients at 2 dose levels for IL2 given with fixed dose of zoledronic acid. Zoledronic acid will be given IV once every 3 weeks, and daily subcutaneous IL2 given weekdays for 2 weeks.
Patients must have evidence of disease and have not received prior antibody therapy with IL2.
See NIH listing for rationale:
To ...
Update on oncolytic virus trials for neuroblastoma
Four oncolytic virus trials open at Cincinnati Children’s for pediatric solid tumors
Dr Tim Cripe provided a very helpful comparison chart for the oncolytic virus trials currently open at Cincinnati Children’s, and permission to post it. To open a PDF of the chart, click on this link:
Viral study comparison (PDF document)
The chart lists the similarities and differences ...
New antibody trials in 2011
Antibodies for relapsed neuroblastoma
Given that recent studies such as COG-3973 [1] and others reveal that half or more of all children with high-risk neuroblastoma are refractory to induction or relapse, and that the majority worldwide never received antibodies as part of frontline treatment, there is currently a significant demand for access to antibody treatment after relapse.
Currently, the only ...
Rational relapse therapy for neuroblastoma
Many therapies, robust rationale needed
For years I have (obsessively) tracked clinical trials and therapies available to children with relapsed and refractory neuroblastoma, driven by hope that curing relapsed NB is possible. Since there are many therapies for “unspecified solid tumors” as well as specifically for neuroblastoma, the resulting variety of trials is quite astounding.
I started ...
Status on oncolytic virus therapies for pediatric solid tumors
A review of a new therapy for neuroblastoma
Significant and accelerating progress is underway in the oncolytic virus arena. In the past decade numerous clinical trials using several different oncolytic viruses against adult cancers have been completed and more are underway. Many trials have shown anti-tumor activity in various adult tumors. A major milestone was reached this year with three oncolytic ...
Temsirolimus and valproic acid trial for relapse neuroblastoma opens
New trial for neuroblastoma opens at University of North Carolina – Chapel Hill
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
This phase I study will enroll 20 patients age 2 to 18 to determine the maximum tolerated dose of temsirolimus in combination with valproic acid, as well as safety, pharmacokinetics, and progression-free ...
CNCF 2010 ~ Dr Kate Matthay presents update on NANT trials
New Approaches to Neuroblastoma Therapy (NANT) consortium offers trials for relapsed and refractory neuroblastoma
Dr Kate Matthay spoke at the Children’s Neuroblastoma Cancer Foundation CNCF parent conference in Chicago July 10, 2010, detailing the status of several NANT trials. She mentioned that these trials open and close periodically, so contacting the principal investigator is the best way ...
CNCF 2010 ~ Dr Giselle Sholler updates on NMTRC trials for neuroblastoma
New drug combinations, personalized medicine proof-of-concept demonstrated, parents involved
Dr Giselle Sholler is the chair for the The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) based at Vermont Children’s Hospital at Fletcher Allen Heath Care, University of Vermont College of Medicine. Dr Sholler presented an update on trials offered by the NMTRC to parents ...
CNCF 2010 ~ Allogeneic (donor) stem cell transplant for neuroblastoma
New donor transplant trial open for relapsed or refractory neuroblastoma
Dr Sandeep Soni spoke at CNCF (Children’s Neuroblastoma Cancer Foundation) Parent Conference in Chicago July 10, 2010. Dr Soni is a member of the Pediatric Blood and Marrow Transplant program at Nationwide Children’s Hospital and an Assistant Professor of Clinical Pediatrics at Ohio State University College of Medicine ...
